Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Management Recommendations for Merkel Cell Carcinoma-A Danish Perspective

Publikation: Bidrag til tidsskriftReviewpeer review

DOI

  1. Small RNAs in Seminal Plasma as Novel Biomarkers for Germ Cell Tumors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. TAM Receptor Inhibition-Implications for Cancer and the Immune System

    Publikation: Bidrag til tidsskriftReviewpeer review

  3. Possible Relevance of Soluble Luteinizing Hormone Receptor during Development and Adulthood in Boys and Men

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Reliable test of clinicians' mastery in skin cancer diagnostics

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Soft tissue myoepithelial carcinoma-a case report with molecular and electron microscopic analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Moving breast implant registries forward: Are they FAIR and Functional?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Merkel cell carcinoma (MCC) is a rare malignant neuroendocrine carcinoma of the skin with a poor prognosis and an apparent increase in incidence. Due to its rarity, evidence-based guidelines are limited, and there is a lack of awareness among clinicians. This review constitutes the consensus management recommendations developed by the Danish MCC expert group and is based on a systematic literature search. Patients with localized disease are recommended surgical excision and adjuvant radiotherapy to the primary site; however, this may be omitted in patients with MCC with low risk features. Patients with regional lymph node involvement are recommended complete lymph node removal and adjuvant radiotherapy in case of extracapsular disease. Metastatic disease was traditionally treated with chemotherapy, however, recent clinical trials with immune therapy have been promising. Immune checkpoint inhibitors targeting the programmed cell death protein 1(PD-1)/programmed death-ligand 1(PD-L1) axis should therefore be strongly considered as first-line treatment for fit patients. A 5-year follow-up period is recommended involving clinical exam every 3 months for 2 years and every 6 months for the following 3 years and PET-CT one to two times a year or if clinically indicated. These national recommendations are intended to offer uniform patient treatment and hopefully improve prognosis.

OriginalsprogEngelsk
Artikelnummer554
TidsskriftCancers
Vol/bind12
Udgave nummer3
Antal sider13
ISSN2072-6694
DOI
StatusUdgivet - 28 feb. 2020

ID: 61916195